Urine miR-21-5p and miR-200c-3p as potential non-invasive biomarkers in patients with prostate cancer.
»
Urine miR-21-5p and miR-200c-3p as potential non-invasive biomarkers in patients with prostate cancer.
To evaluate miR-21-5p and miR-200C-3p expression in the urine of patients with prostate cancer (PCa) and to investigate their potential as biomarkers.The urine samples collected from 80 patients, including 20 patients who were diagnosed with benign prostatic hyperplasia ( BPH) and 60 patients diagnosed with PCa, were examined. The exosome isolation is done by using miRCURY exosome isolation kit (Exiqon, Denmark), total RNA was extracted using the miRCURY RNA Isolation Kit-Biofluid kit (Exiqon, Denmark), and complementary DNA (cDNA) was synthesized using a kit Universal cDNA Synthesis (Exiqon, Denmark ).
A quantitative polymerase chain reaction (qPCR) analysis of gene expression was performed using qPCR CFX 96 thermocycler (Bio-Rad). All procedures followed by manufacturers recommendations.The overexpressions of miR-21 in a group of non-metastatic PCa and metastatic PCa compared with BPH group was statistically significant with p-values of 0.001 and 0.018, respectively. The non-metastatic PCa compared with metastatic PCa group was also statistically significant with a p-value of 0.037. Under the expression of miR-200C in non-metastatic PCa and PCa metastasis group compared to the BPH group was statistically significant with p-values of 0.001 and 0.001, respectively.
The overexpressions of miR-21 was found in this study could be a potential non-invasive diagnostic tool for patients with PCa. Despite the significant results in our study, the use of micro-RNA in urine samples may vary due to epigenetic variation. Further studies with a larger population is needed to investigate the role of miR-21 and miR-200C as biomarkers in PCa.
Urine miR-21-5p and miR-200c-3p as potential non-invasive biomarkers in patients with prostate cancer.
Circulating microRNAs in extracellular vesicles as a potential biomarker for psoriatic arthritis in patients with psoriasis.
Psoriatic arthritis (PsA) develops in ~ 30% of patients with psoriasis. The diagnosis of PsA challenging and there is no reliable molecular markers in clinical use. MicroRNAs are short noncoding regulatory RNAs, which can be actively packaged in extracellular vesicles (EV) and secreted into circulation.To investigate whether plasma-derived microRNAs EV can serve as a biomarker for PsA in patients with psoriasis.
METHOD plasma samples obtained from patients with psoriasis the skin only (PSC) and patients with psoriasis and PsA. EVS plasma was isolated using Exosome miRCURYTM Isolation Kit. RNA sequencing was used to identify differentially expressed miRNAs EV in discovery phase (PSC, n = 15; PsA, n = 14). In the validation phase (PSC, n = 29; PsA, n = 28), 41 miRNAs been analyzed in plasma EVs by qPCR. Association of miRNAs identified with PsA assessed by logistic regression analysis.
RNA sequencing identified 19 miRNAs EV plasma levels differed significantly between PsA and PSC in the category of inventions. significantly lower levels of let-7b plasma EV-5p and miR-30e-5p in PsA vs. PSC confirmed in the validation cohort, and decreased their levels found to be associated with the presence of PsA. ROC analysis revealed AUC of 0.68 (95% CI 0.53 to 0.83) for the let-7b-5p and 0.69 (95% CI from 0.55 to 0.84) to the level of miR-30e-5p.Circulating EV microRNA altered in patients with PsA compared with the PSC. The findings of this exploratory study shows that circulating microRNAs EV can serve as a biomarker for arthritis in patients with psoriasis.
The main objective of this research is to develop nano-drug consisting of doxorubicin and exosome derived from mesenchymal stem cells, and to explore its effect on osteosarcoma in vitro.The exosomes isolated from bone marrow MSCs (BM-MSC) by Exosome Isolation Kit.
PEG-it Virus Precipitation Solution (100 mL aliquot)
Rat Complete SeraMir Exosome RNA Amplification and Profiling Kit for Media and Urine (contains cat# RA800TC-1 with 50ml ExoQuick-TC, RA805A-1 and RA812A-1 components)
The exosome-loaded doxorubicin (Exo-Dox) is made by mixing exosome with Dox-HCl, desalinizing with triethylamine and then dialyzing against PBS overnight. Nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM) was used to characterize of exosome and Exo-Dox.
